Correlates of Obesity Medication Use in Paediatric Weight Management Programmes: A POWER Consortium Analysis
Pediatric Obesity · 2026
DOI: 10.1111/ijpo.70127 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Obesity, 2026. Verfasst von Amy L Christison und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Illinois College of Medicine at Peoria, Peoria, Illinois, USA. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Pediatric Obesity, Weight Reduction Programs, Practice Patterns, Physicians'. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Introduction
The national POWER registry of paediatric weight management programmes reported increased obesity medication (ObM) use in recent years. However, factors influencing ObM prescribing are not well understood. This study aimed to compare (1) clinical characteristics between youth prescribed ObMs and those who were not and (2) prescribing patterns among programmes.
Methods
Data from youth aged 6–18 years seen at 12 POWER sites between 2018 and 2024 were analysed. Clinical and demographic variables were compared between ObM and non‐ObM groups using Fisher's exact test and logistic regression, adjusting for site. Site‐level prescribing patterns were assessed using χ 2 and Fisher's exact tests.
Results
ObMs were prescribed to 927 of 4628 (20%) patients. Topiramate (37%) and metformin (43%) were the most prescribed. ObM patients were older [12–15 years aOR (CI) = 1.7 (1.4, 2.0); 16–18 years aOR (CI) = 1.6 (1.3, 2.0) vs. 6–11 years], had more severe obesity [Class 2 aOR (CI) = 1.6 (1.3, 2.2); Class 3 aOR (CI) = 2.9 (2.3, 3.8) vs. Class 1] and had more obesity related co‐morbidities, but demographic characteristics were not different. Higher prescribing programmes offered ObMs sooner and multiple ObMs more often.
Conclusions
ObM prescribing was strongly associated with age, obesity severity and comorbidities, highlighting the need for prospective studies on earlier initiation to prevent disease progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, University of Illinois College of Medicine at Peoria, Peoria, Illinois, USA.
- Cleveland Clinic Children's Section for Pediatric Endocrinology, Cleveland, Ohio, USA.
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- Children's Mercy Kansas City, Center for Children's Healthy Lifestyles & Nutrition, University of Missouri Kansas City, Kansas City, Missouri, USA.
- Columbia U Medical Center, New York, New York, USA.
ORCID-Profile: Amy L Christison, Vidhu Thaker, Alaina P Vidmar, Jennifer K Yee
Zitieren
APA
Christison, A. L., Kim, R., King, E., Sahay, R., Kharofa, R., Sweeney, B. R., Thaker, V., Tucker, J. M., Vidmar, A. P., Yee, J. K., & Kirk, S. (2026). Correlates of Obesity Medication Use in Paediatric Weight Management Programmes: A POWER Consortium Analysis. Pediatric Obesity. https://doi.org/10.1111/ijpo.70127
Vancouver
Christison AL, Kim R, King E, Sahay R, Kharofa R, Sweeney BR, et al. Correlates of Obesity Medication Use in Paediatric Weight Management Programmes: A POWER Consortium Analysis. Pediatric Obesity. 2026. doi:10.1111/ijpo.70127
BibTeX
@article{Christison2026,
author = {Christison, Amy L and Kim, Roy and King, Eileen and Sahay, Rashmi and Kharofa, Roohi and Sweeney, Brooke R and Thaker, Vidhu and Tucker, Jared M and Vidmar, Alaina P and Yee, Jennifer K and Kirk, Shelley},
title = {Correlates of Obesity Medication Use in Paediatric Weight Management Programmes: A POWER Consortium Analysis},
journal = {Pediatric Obesity},
year = {2026},
doi = {10.1111/ijpo.70127}
}
EUVIMED